Ernst de Bruijn

825 citations

22 papers · 561 indexed · h-index 14

Oncology top 10%
- Cancer Risks and Factors 3
- Colorectal Cancer Treatments and Studies 3
- Cancer Treatment and Pharmacology 2
Biotechnology top 10%
- Cancer Research and Treatments 3
Gastroenterology top 10%
Pediatrics, Perinatology and Child Health top 10%
Obstetrics and Gynecology
Hepatology
- Hepatocellular Carcinoma Treatment and Prognosis 4
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 3
Toxicology
- Bioactive Compounds and Antitumor Agents 2
Hematology
- Chronic Myeloid Leukemia Treatments 2

Co-authors: Liesbeth Heyns René Verbesselt Kristel Van Calsteren Frédéric Amant Rieta Van Bree Jan de Hoon Daniel Chai Gert De Boeck
Cited by: Oncology Biotechnology Gastroenterology
Journals: Clinical Cancer Research (1 paper)British Journal of Cancer (1 paper)Annals of Oncology (1 paper)
Partner nations: Belgium Netherlands Switzerland

In The Last Decade

Ernst de Bruijn

21 papers receiving 542 citations

Peers

Countries citing papers authored by Ernst de Bruijn

Since Specialization

Citations

This map shows the geographic impact of Ernst de Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernst de Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernst de Bruijn more than expected).

Fields of papers citing papers by Ernst de Bruijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernst de Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernst de Bruijn. The network helps show where Ernst de Bruijn may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ernst de Bruijn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ernst de Bruijn Line = papers co-authored together Ernst de Bruijn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Multicenter Phase II Clinical Trial of Isolated Lung Perfusion in Patients With Lung Metastases The Annals of Thoracic Surgery ·Paul A. J. Beckers,Michel I.M. Versteegh,Thomas J. van Brakel,Jerry Braun,Bart Van de Putte,Alexander P.W.M. Maat,Wim Vergauwen,Inez Rodrigus,Willem den Hengst,Filip Lardon,Ernst de Bruijn,Gunther Guetens,Gert De Boeck,Jan F. Gielis,Patrick Lauwers,Laurens Denissen,Jeroen Hendriks,Paul Van Schil	2019	15
2	Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry Rapid Communications in Mass Spectrometry ·Jasper Boschmans,Ernst de Bruijn,Paul Van Schil,Filip Lemière	2013	11
3	Substantial Variation in Transplacental Transfer of Chemotherapeutic Agents in a Mouse Model Reproductive Sciences ·Kristel Van Calsteren,René Verbesselt,Rieta Van Bree,Liesbeth Heyns,Ernst de Bruijn,Jan de Hoon,Frédéric Amant	2010	43
4	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study Acta Obstetricia Et Gynecologica Scandinavica ·Kristel Van Calsteren,René Verbesselt,Nelleke Ottevanger,M Halaška,Liesbeth Heyns,Rieta Van Bree,Ernst de Bruijn,Daniel Chai,Michel Delforge,Lucien Noens,Vincent Renard,Els O. Witteveen,Lukáš Rob,Jan de Hoon,Frédéric Amant	2010	81
5	Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. PubMed ·Kristel Van Calsteren,René Verbesselt,Roland Devlieger,Luc De Catte,Daniel Chai,Rieta Van Bree,Liesbeth Heyns,Jos H. Beijnen,Sonia Demarsin,Ernst de Bruijn,Jan de Hoon,Frédéric Amant	2010	81
6	Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial Journal of Surgical Oncology ·Marco Grootenboers,Jeroen Hendriks,Wim Jan van Boven,Catherijne A. J. Knibbe,Bart Van de Putte,Bernard Stockman,Ernst de Bruijn,Jan B. Vermorken,Paul Van Schil,Franz M.N.H. Schramel	2007	12
7	Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines Pharmacology ·Hans Prenen,Gunther Guetens,Gert De Boeck,Maria Dêbiec‐Rychter,Paul W. Manley,Patrick Schöffski,Allan T. van Oosterom,Ernst de Bruijn	2006	55
8	Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR Clinical Cancer Research ·Josep Tabernero,Patrick Schöffski,Federico Rojo,Ernst de Bruijn,FJ Ramos,Herlinde Dumez,Teresa Macarulla,Hans Prenen,E. Casado,Gunther Guetens,Peralta,J. Moreno Jiménez,JM del Campo,N. Gascón,Santiago Ramón y Cajal,E. Martinelli,E. Jiménez,A. Van Oosterom,José Baselga	2005	4
9	Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane American journal of biochemistry & biotechnology ·Hans Prenen,Cristiana Stefan,Bart Landuyt,Peter Vermaelen,Maria Debiec-Ryc,Mathieu Bollen,Sigrid Stroobants,Ernst de Bruijn,Luc Mortelmans,Raf Sciot,Patrick Schöffski,A. van Oosterom	2005	17
10	Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial The Annals of Thoracic Surgery ·Jeroen Hendriks,Marco J.J.H. Grootenboers,Franz M.N.H. Schramel,Wim Jan van Boven,Bernard Stockman,Cornelis A. Seldenrijk,P. ten Broecke,Catherijne A. J. Knibbe,P. H. Th. J. Slee,Ernst de Bruijn,R. Vlaeminck,Jos Heeren,Jan B. Vermorken,Bart Van de Putte,Sander Romijn,Eric Van Marck,Paul Van Schil	2004	48
11	Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours British Journal of Cancer ·Tom Dresselaers,Jan Theys,Sandra Nuyts,Bradly G. Wouters,Ernst de Bruijn,Jozef Anné,Philippe Lambin,Paul Van Hecke,Willy Landuyt	2003	29
12	Pharmacokinetics after pulmonary artery perfusion with gemcitabine The Annals of Thoracic Surgery ·Bart P. van Putte,Jeroen Hendriks,Sander Romijn,Bea Pauwels,Gert De Boeck,Gunther Guetens,Ernst de Bruijn,Paul Van Schil	2003	14
13	Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes Cancer Investigation ·Willy Landuyt,Jan Theys,Sandra Nuyts,M. Drijkoningen,Jack Fowler,Alex Reijnders,Sandra Liekens,Johan Neyts,Ernst de Bruijn,Jozef Anné,Philippe Lambin	2001	2
14	Pharmacokinetics of Ifosfamide Are Changed by Combination With Docetaxel American Journal of Clinical Oncology ·D. Schrijvers,L. Pronk,Martin Highley,René Bruno,D. Locci-Tonelli,Ernst de Bruijn,A.T. van Oosterom,Jaap Verweij	2000	17
15	KW-2149-induced pulmonary toxicity is not prevented by corticosteroids Anti-Cancer Drugs ·D. Schrijvers,G. Catimel,Martin Highley,F. Höppener,Luc Dirix,Ernst de Bruijn,J.P. Droz,AT van Oosterom	1999	7
16	Vascular endothelial growth factor (VEGF): Plasma is the place to be Annals of Oncology ·Wim Wynendaele,Rita Derua,Marc Hoylaerts,Adam Pawinski,Etienne Waelkens,Ernst de Bruijn,Wilfried Merlevede,Robert Paridaens,A. van Oosterom	1998	2
17	Colonisation ofClostridiumin the body is restricted to hypoxic and necrotic areas of tumours Anaerobe ·Philippe Lambin,Jan Theys,Willy Landuyt,Paul F.J.W. Rijken,Albert van der Kogel,E. van der Schueren,R.J. Hodgkiss,Jack Fowler,Sandra Nuyts,Ernst de Bruijn,Lieve Van Mellaert,Jozef Anné	1998	73
18	Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion Investigational New Drugs ·Luc Dirix,G. Catimel,René Verdonk,Ernst de Bruijn,Brigitte Tranchand,C Ardiet,A. van Oosterom	1995	2
19	Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149 Anti-Cancer Drugs ·Luc Dirix,G. Catimel,I. Koier,A. Prové,Dirk Schrijvers,Erik Joossens,Ernst de Bruijn,C Ardiet,Eric Evène,A Dumortier,Michel Clavel,A. van Oosterom	1995	13
20	Multidrug Resistance in Rat Colon Carcinoma Cell Lines CC531, CC531^mdr+ and CC531^rev Japanese Journal of Cancer Research ·E. Gheuens,S. Van der Heyden,Hilde Elst,Alexander M.M. Eggermont,A. van Oosterom,Ernst de Bruijn	1993	13

About Ernst de Bruijn

Ernst de Bruijn is a scholar working on Toxicology, Hepatology and Gastroenterology, having authored 22 papers that have together received 561 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer Research and Treatments (3 papers), Cancer Risks and Factors (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Bioactive Compounds and Antitumor Agents (2 papers), Cancer Treatment and Pharmacology (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). The work is most often cited by research in Oncology (281 citations), Biotechnology (78 citations) and Gastroenterology (48 citations). Ernst de Bruijn has collaborated with scholars based in Belgium, Netherlands and Switzerland. Frequent co-authors include Liesbeth Heyns, René Verbesselt, Kristel Van Calsteren, Frédéric Amant, Rieta Van Bree, Jan de Hoon, Daniel Chai, Gert De Boeck, Gunther Guetens and Patrick Schöffski. Their work appears in journals such as Clinical Cancer Research, British Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact